SCHEMBL20801118

SCHEMBL20801118

COCC(=O)C1(O)Cc2c(O)c3c(c(O)c2C(OC2CC(N)C(O)C(C)O2)C1)C(=O)c1c(OC)cccc1C3=O

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 10/20 0.88
KMT2A Q03164 10/20 0.88
THRB P10828 9/20 0.88
BLM P54132 9/20 0.88
RECQL P46063 7/20 0.88
HIF1A Q16665 6/20 0.88
SMN1; SMN2 Q16637 6/20 0.88
BRCA1 P38398 6/20 0.88
TDP1 Q9NUW8 6/20 0.88
MAPT P10636 6/20 0.88
HTT P42858 5/20 0.88
TOP2A P11388 4/20 0.88
MAPK1 P28482 4/20 0.88
STAT6 P42226 4/20 0.88
CHRM1 P11229 3/20 0.88
TBXA2R P21731 3/20 0.88
KDM4E B2RXH2 3/20 0.88
ALDH1A1 P00352 3/20 0.88
ABCB1 P08183 3/20 0.88
PTGS1 P23219 3/20 0.88

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22513656 1.00 MEN1 (0.88) MEN1KMT2ATHRBBLMRECQL
SCHEMBL17899481 1.00 MEN1 (0.88) MEN1KMT2ATHRBBLMRECQL
SCHEMBL17899465 1.00 MEN1 (0.88) MEN1KMT2ATHRBBLMRECQL
SCHEMBL13742595 1.00 MEN1 (0.88) MEN1KMT2ATHRBBLMRECQL
SCHEMBL14867492 0.96 MEN1 (0.88) MEN1KMT2ATHRBBLMRECQL
Epirubicin SCHEMBL24421866 0.94 MEN1 (1.00) MEN1KMT2ATHRBBLMRECQL
Epirubicin SCHEMBL21914951 0.94 MEN1 (1.00) MEN1KMT2ATHRBBLMRECQL
Epirubicin SCHEMBL21184881 0.94 MEN1 (1.00) MEN1KMT2ATHRBBLMRECQL
Epirubicin SCHEMBL14596255 0.94 MEN1 (1.00) MEN1KMT2ATHRBBLMRECQL
Epirubicin SCHEMBL8582 0.94 MEN1 (1.00) MEN1KMT2ATHRBBLMRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190076544-A1 FORMULATIONS FOR IMPROVING THE EFFICACY OF HYDROPHOBIC DRUGS PEPTINOVO BIOPHARMA, LLC (US) 2019-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190076544-A1 FORMULATIONS FOR IMPROVING THE EFFICACY OF HYDROPHOBIC DRUGS IAPP, CETP, ANXA6 MEN1 646/4885KMT2A 4736/4885THRB 2593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.